Key result
Colchicine disrupts human macrophage microtubules, reducing footprint area by ~50% and limiting matrix degradation.
Why the study?
Colchicine reduces cardiovascular events in patients with recent acute or chronic coronary disease, but the underlying mechanisms remain incompletely understood.
Does low-dose colchicine inhibit macrophage motility and matrix degradation through microtubule disruption in human and mouse macrophages?
Does low-dose colchicine inhibit macrophage motility and matrix degradation through microtubule disruption in human and mouse macrophages?
Low-dose colchicine inhibits macrophage motility and matrix degradation via microtubule disruption, providing a mechanistic basis for its cardiovascular benefits in atherosclerosis.
Answers are grounded in this paper and cite their sources.
Does not support changing colchicine use; leaves open whether microtubule disruption mediates benefits in atherosclerosis.
Atherosclerosis is a chronic inflammatory process wherein macrophages play a central role in the evolution of arterial wall plaques in extracellular matrix. Colchicine, a drug used most commonly to treat gout, reduces immune cell motility and recruitment to inflamed joints by targeting microtubules. Colchicine also reduces cardiovascular events in patients with recent acute or chronic coronary disease, but the mechanisms are incompletely understood. To characterise the effect of low-dose colchicine on human and mouse macrophages, focusing on the microtubule cytoskeleton and macrophage function. Human monocytes were isolated from buffy coats and differentiated into macrophages (huMDM) in culture medium. Mouse bone marrow-derived macrophages (msBMM) were extracted from C57BL/6 mice and grown in culture medium to produce mature adherent macrophages. HuMDM treated with 10 nM colchicine showed marked morphological and functional changes associated with disruption of the microtubule cytoskeleton. Colchicine reduced the footprint area of huMDM by almost 50% and matrix degradation by 20%. In contrast, colchicine minimally affected the morphology of msBMM. However, it reduced the density of the microtubule cytoskeleton at the leading edge of msBMM with detectable disruption of microtubules, resulting in a significant decrease in motility. While msBMM appeared less susceptible to low-dose colchicine than huMDM, there was a measurable effect on their microtubules that resulted in reduced motility. Inhibition of huMDM matrix degradative capacity may contribute to colchicine's effect in reducing cardiovascular events. • Anti-inflammatory drug, colchicine, affected macrophages, crucial to atherosclerosis. • Human macrophages showed marked morphological and functional changes after colchicine. • These changes were associated with a loss of the microtubule cytoskeleton. • Colchicine lowered microtubule density in mouse macrophages, inhibiting motility. • Macrophage effects of colchicine may aid the stabilisation of atherosclerotic plaques.
No takes yet. Share an insight, caveat, or question.
Vansjariya et al. (2026) studied Atherosclerosis. Colchicine was evaluated on Macrophage morphology, motility, and matrix degradation. Treatment with 10 nM colchicine disrupted the microtubule cytoskeleton in human macrophages, reducing their footprint area by almost 50% and matrix degradation by 20%.
Synapse has enriched 10 related papers. Consider them for comparative context: